A new physiologic framework for pressure injury prevention.
Pressure ulcers persist across every care setting despite decades of effort and investment. The reason is not inadequate technology. It is an incomplete problem definition. MI Medical was built around a different requirement entirely.
Systematic reviews consistently conclude that no support surface class has demonstrated superiority in preventing pressure ulcers, and that evidence is of low to moderate certainty. The problem is not effort. It is framing.
Interface pressure reduction became the governing metric because pressure is measurable. But it is a proxy — and an unvalidated one. A system can produce favorable pressure readings while the tissue beneath continues to experience perfusion impairment. The reading appears safe. The injury develops anyway.
Pressure-induced injury is governed by time-dependent ischemia. Capillary perfusion must be restored at high-risk anatomic sites — completely, at defined intervals, for defined durations. Partial pressure reduction does not satisfy this requirement. Only complete unloading does.
Manual repositioning is nominally deterministic. In practice it is not. Staffing ratios, shift changes, competing care demands, and patient cooperation each introduce variability that prevents the physiologically necessary event from occurring at the required time, location, and duration.
Every support surface in clinical use is covered by a continuous sheet or mattress cover. When any underlying unit attempts localized unloading, the overlying cover bridges the gap — reintroducing pressure at the exact site where unloading was attempted. This is structural, not incidental.
Intentional Skin Vacation is the governing physiologic construct: the deliberate, scheduled, and complete withdrawal of mechanical support from specific anatomic regions to enable capillary reperfusion and metabolic recovery. It has three non-negotiable requirements.
Partial reduction of interface pressure is not equivalent to complete unloading. The system must achieve near-total withdrawal of mechanical support sufficient to permit capillary reperfusion — not merely soften the surface or reduce peak pressure. The threshold is physiologic, not mechanical.
The unloading event must persist long enough to enable meaningful physiologic recovery and recur at intervals that prevent ischemic debt from accumulating to injurious levels. Animal model data indicate reversible inflammation at 1.5 hours of ischemia; non-reversible damage at 2–3 hours.
If recovery depends on a caregiver being present, available, and technically correct at each interval, it is not reliably scheduled — it is occasionally achieved. The recovery event must be produced by the system itself, independent of human execution variability. A protocol defines intent. A system produces the outcome.
The development of the VISA Care System was not a search for a better mattress. It was a six-year engineering effort to satisfy a physiologic requirement that no existing device was designed to meet.
Air-driven bellows across a full 30×80 inch bed. Established the foundational design premise — deliberate, scheduled contact vacation — and exposed the governing mechanical problem: shear. Lateral movement in the bellows compromised stability in ways that proved resistant to refinement within that architecture.
Foundational concept provenAir cylinders replaced bellows, solving the shear problem with precision. Confirmed the cylinder approach was mechanically superior. Also confirmed that mechanical superiority within the same pneumatic architecture was insufficient — weight exceeded 500 lbs, complexity remained unresolved, sanitation unaddressed. A better answer to the wrong question is still the wrong answer.
Shear eliminated; architecture reconsideredManifold architecture replaced individual cylinder assemblies, simplifying the pneumatic network and significantly reducing system complexity. High resolution, fully programmable, sensor-ready architecture built in from the outset. The flagship of the product line — designed for acute care environments where complexity is justified by clinical requirement. Runs today on clinician-defined timed sequences, fully autonomous.
Flagship — acute care readyFirst departure from pneumatic complexity. Single drive source, mechanically timed, delivering 2 to 2.5 inches of vertical motion. Proved that independent modular units could work. Open mechanical structure identified sanitation as the governing design requirement for any viable modular bed — that lesson became the foundation of VSM 5.
Modular architecture proven; seating applicationT-shaped alloy bars with quick-release foam and individually mounted waterproof covers. When a module retracts, its cover retracts with it — eliminating the hammocking effect that defeats unloading in every system using a continuous overlay. True contact break at the skin interface, not only at the mechanical level beneath it. 300 lbs per bar. Two years of load testing without failure. The same actuator assembly reconfigures across LTC, bariatric, pediatric, heel offloading, surgical, and wheelchair applications through dimensional selection alone.
Production ready — sanitation solved — contact break verifiedThe VISA Care System is a production-ready platform with a filed provisional patent, two years of mechanical validation, and a scientific framework awaiting clinical partnership. We are not overstating what we have. We are clear about what comes next.
Provisional utility patent filed covering all four embodiments. Non-provisional in preparation. Four foundational claims in dependent chain covering verified contact break at the skin interface, per-unit cover architecture, system resolution commensurate with anatomic risk sites, and outcome accountability supported by published animal model evidence. Sixty engineering drawings support the filing.
Two years of continuous load testing at 300 lbs per module without mechanical failure. Sanitation protocol validated. Quick-release component architecture confirmed in clinical workflow simulation. VSM 5 is production-ready.
The Tissue Recovery Paradigm white paper establishes the governing physiologic framework, defines the failure mode of existing approaches, and articulates the system requirements for deterministic prevention. Available to qualified clinical and research contacts on request.
The appropriate next step is a clinical feasibility study designed around recovery-event endpoints rather than pressure surrogates. We are seeking a clinical partner with interest in wound care outcomes research and access to a high-risk patient population. IRB protocol in development.
510(k) clearance pathway identified. Pre-submission strategy in development. Clinical validation designed around recovery-event endpoints will support a regulatory argument for a better surrogate than interface pressure reduction — one that the field currently lacks.
MI Medical is open to conversations with strategic partners and acquirers who understand the scale of the unresolved prevention problem and the clinical significance of a system designed to address it at the physiologic level. The platform architecture supports applications across clinical, veterinary, and personal support markets.
Three documents constitute the full MI Medical evidentiary package. They are available to clinical researchers, health system evaluators, potential partners, and qualified investors.
The governing scientific framework. Defines the failure mode of existing prevention strategies and the system requirements for deterministic recovery assurance.
The complete engineering record across five prototype generations. Documents the design decisions, testing results, and architecture of the production-ready SpanBar system.
One-page mechanistic comparison of recovery-assurance versus redistribution-based standard of care, evaluated against nine governing criteria.
Enter your name and institutional email to receive the documentation package directly. We respond to all requests within one business day.
Documentation is provided to clinical researchers, health system professionals, potential partners, and qualified investors. We do not share your information.
We will follow up at the email address you provided within one business day with the complete documentation package.